The transfer of a laboratory based hypothesis to a clinically useful therapy: the development of anti-TNF therapy of rheumatoid arthritis.
The development of anti-TNF therapy is a key step forward in rheumatology as it is the first new therapy for based on investigating the molecular mechanisms of this disease. This chapter reviews how this discovery was made.
Feldmann
Marc
M
Kennedy Institute of Rheumatology Division, Imperial College, 1 Aspenlea Road, Hammersmith, London W6 8LH, UK. m.feldmann@imperial.ac.uk
Brennan
Fionula M
FM
Williams
Richard O
RO
Woody
James N
JN
Maini
Ravinder N
RN
D000818:Animals; D018501:Antirheumatic Agents / Q000627:therapeutic use; D001172:Arthritis, Rheumatoid / Q000188:drug therapy* / Q000276:immunology*; D001323:Autoantibodies / Q000032:analysis / Q000187:drug effects; D002986:Clinical Trials as Topic; D016207:Cytokines / Q000187:drug effects* / Q000378:metabolism; D004195:Disease Models, Animal; D006801:Humans; D051379:Mice; D012333:RNA, Messenger / Q000032:analysis; D012107:Research Design; D012680:Sensitivity and Specificity; D013583:Synovial Membrane / Q000187:drug effects / Q000378:metabolism; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors* / Q000627:therapeutic use
D018501:Antirheumatic Agents; D001323:Autoantibodies; D016207:Cytokines; D012333:RNA, Messenger; D014409:Tumor Necrosis Factor-alpha